Table 1.
Patient characteristics.
Fig 1.
Institutional checklist used for treatment approval and workflow on the MR Linac.
Fig 2.
Improved visualization with 1.5 Tesla MRI as compared with CT on rails.
Table 2.
Selection considerations for MR-Linac treatment and ATP versus ATS.
Fig 3.
a. Aggregate contours for pancreatic ATS case illustrating daily small bowel and pancreatic CTV position differences, CTV (pink), small bowel (yellow). b. ADC measured during treatment with radiation, with increase in median ADC value during SBRT.
Table 3.
Dose constraints used for SBRT for abdominal metastatic lesions or primary hepatocellular carcinoma, DVH Criteria, 5 fraction constraints.